Literature DB >> 33173380

Prevention and treatment of cancer-associated thrombosis.

S Ng1, M Carrier1.   

Abstract

Cancer is a hypercoagulable state with an associated increased risk of venous thromboembolism (vte) that is further amplified in individuals who undergo chemotherapy. Compared with patients having cancer alone or vte alone, patients who develop cancer-associated vte have a significantly poorer prognosis. The risks of recurrent vte despite appropriate anticoagulation therapy and of bleeding are also higher in patients with cancer than in those without. For those reasons, the prevention and appropriate management of cancer-associated thrombosis is of paramount importance. Although low-molecular-weight heparin has been the standard of care for the prevention and treatment of cancer-associated thrombosis, direct oral anticoagulants are increasingly being adopted as an effective and safe alternative. 2020 Multimed Inc.

Entities:  

Keywords:  Venous thromboembolism; anticoagulation; cancer-associated thrombosis; direct oral anticoagulants; thromboprophylaxis

Year:  2020        PMID: 33173380      PMCID: PMC7606049          DOI: 10.3747/co.27.6873

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  26 in total

1.  Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study.

Authors:  J-P Galanaud; M-A Sevestre; G Pernod; C Genty; S Richelet; S R Kahn; C Boulon; H Terrisse; I Quéré; J-L Bosson
Journal:  J Thromb Haemost       Date:  2017-04-21       Impact factor: 5.824

2.  Rare thromboses of cerebral, splanchnic and upper-extremity veins. A narrative review.

Authors:  Ida Martinelli; Valerio De Stefano
Journal:  Thromb Haemost       Date:  2010-03-29       Impact factor: 5.249

3.  Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study.

Authors:  Noémie Kraaijpoel; Suzanne M Bleker; Guy Meyer; Isabelle Mahé; Andrés Muñoz; Laurent Bertoletti; Annemarieke Bartels-Rutten; Jan Beyer-Westendorf; Ettore Porreca; Carine Boulon; Nick van Es; Diana I Iosub; Francis Couturaud; Mercedes Biosca; Teresa Lerede; Philippe Lacroix; Anthony Maraveyas; Anita Aggarwal; Philippe Girard; Harry R Büller; Marcello Di Nisio
Journal:  J Clin Oncol       Date:  2019-05-22       Impact factor: 44.544

4.  Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.

Authors:  J A Heit; M D Silverstein; D N Mohr; T M Petterson; W M O'Fallon; L J Melton
Journal:  Arch Intern Med       Date:  2000-03-27

Review 5.  Cancer-associated venous thromboembolism: Burden, mechanisms, and management.

Authors:  Cihan Ay; Ingrid Pabinger; Alexander T Cohen
Journal:  Thromb Haemost       Date:  2016-11-24       Impact factor: 5.249

Review 6.  Epidemiology of cancer-associated venous thrombosis.

Authors:  Jasmijn F Timp; Sigrid K Braekkan; Henri H Versteeg; Suzanne C Cannegieter
Journal:  Blood       Date:  2013-08-01       Impact factor: 22.113

7.  Pulmonary embolism in oncologic patients: frequency and embolus burden of symptomatic and unsuspected events.

Authors:  Andreas Gunter Bach; Hans-Joachim Schmoll; Christoph Beckel; Curd Behrmann; Rolf Peter Spielmann; Andreas Wienke; Jasmin Abbas; Alexey Surov
Journal:  Acta Radiol       Date:  2013-07-17       Impact factor: 1.990

8.  Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.

Authors:  Giancarlo Agnelli; Cecilia Becattini; Guy Meyer; Andres Muñoz; Menno V Huisman; Jean M Connors; Alexander Cohen; Rupert Bauersachs; Benjamin Brenner; Adam Torbicki; Maria R Sueiro; Catherine Lambert; Gualberto Gussoni; Mauro Campanini; Andrea Fontanella; Giorgio Vescovo; Melina Verso
Journal:  N Engl J Med       Date:  2020-03-29       Impact factor: 91.245

9.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

Authors:  Annie M Young; Andrea Marshall; Jenny Thirlwall; Oliver Chapman; Anand Lokare; Catherine Hill; Danielle Hale; Janet A Dunn; Gary H Lyman; Charles Hutchinson; Peter MacCallum; Ajay Kakkar; F D Richard Hobbs; Stavros Petrou; Jeremy Dale; Christopher J Poole; Anthony Maraveyas; Mark Levine
Journal:  J Clin Oncol       Date:  2018-05-10       Impact factor: 44.544

10.  Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis.

Authors:  Alok A Khorana; Keith R McCrae; Dejan Milentijevic; Jonathan Fortier; Winnie W Nelson; François Laliberté; Concetta Crivera; Patrick Lefebvre; Daniel Yannicelli; Jeff Schein
Journal:  Res Pract Thromb Haemost       Date:  2017-05-30
View more
  1 in total

Review 1.  Characteristics and Treatment Strategy of Isolated Calf Deep Venous Thrombosis after Fractures: A Review of Recent Literature.

Authors:  Wei-Guang Zhao; Ji-Ying Yan; Xiao-Lei Li; Cai-Ying Shi; Zhi-Yun Wang; Wei Guo; Kai Zhang; Wei-Li Zhang; Xiao-Chuan Jia; Shu-Bei Cui; Li-Qiang Jiang; Jian-Long Zhao; Zhen-Wu Liu; Zhao-Hui Yang; Li Liu; Ying-Ze Zhang
Journal:  Orthop Surg       Date:  2022-04-28       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.